Olpasiran

Amgen · AMG 890

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
10 in total · 3 in the EU
Targets
 

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.Lp(a) small interfering RNA (siRNA)
Tested for
Cardiovascular Disease (2 trials), Atherosclerotic Cardiovascular Disease
Main trialPhase 3
“The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).”In the company’s words, NCT05581303 on ClinicalTrials.gov
Other names
AMG 890 · ARO-LPA

Other drugs for Cardiovascular Disease

All 536 drugs for Cardiovascular Disease

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 Mar 2028 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Phase 3Recruiting 15 Jun 2028 Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
Phase 3Recruiting 20 Oct 2031 OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
Phase 2Completed 27 Dec 2021 Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Phase 1Completed 12 Nov 2021 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
Phase 1Completed 5 Apr 2023 A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
Phase 1Completed 18 Apr 2023 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
Phase 1Completed 24 Oct 2023 A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
Phase 1Completed 29 Nov 2024 A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
Phase 3Authorised not given A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Olpasiran

Following is part of Solo: you see every change to Olpasiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in